XTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise

BioPharma DiveMerck still sees ‘compelling’ outlook for Terns leukemia drug

CellProteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function

CellDifferential inhibition of Morbillivirus and Henipavirus polymerases by ERDRP-0519 and structure-guided inhibitor optimization

BioPharma DiveUniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

Endpoints NewsAvalyn's upsized IPO; Alector ends another study in GSK partnership

Endpoints NewsAnalysts focus on three programs in big year for Bristol Myers

BioPharma DiveLilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

Endpoints NewsXTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise

Lonza NewsHigh-throughput chromatography in bioprocess analytics - News-Medical

FierceBiotechIndivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2

FierceBiotechBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific

Endpoints NewsWhat we heard at a health tech conference in Boston